Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2015-09

AUTHORS

Jörg Tomeczkowski, Ansgar Lange, Andreas Güntert, Pushpike Thilakarathne, Joris Diels, Liang Xiu, Peter De Porre, Christoph Tapprich

ABSTRACT

INTRODUCTION: Among patients with acute myeloid leukemia (AML), the DACO-016 randomized study showed reduction in mortality for decitabine [Dacogen(®) (DAC), Eisai Inc., Woodcliff Lake, NJ, USA] compared with treatment choice (TC): at primary analysis the hazard ratio (HR) was 0.85 (95% confidence interval 0.69-1.04; stratified log-rank P = 0.108). With two interim analyses, two-sided alpha was adjusted to 0.0462. With 1-year additional follow-up the HR reached 0.82 (nominal P = 0.0373). These data resulted in approval of DAC in the European Union, though not in the United States. Though pre-specified, the log-rank test could be considered not optimal to assess the observed survival difference because of the non-proportional hazard nature of the survival curves. METHODS: We applied the Wilcoxon test as a sensitivity analysis. Patients were randomized to DAC (N = 242) or TC (N = 243). One-hundred and eight (44.4%) patients in the TC arm and 91 (37.6%) patients in the DAC arm selectively crossed over to subsequent disease modifying therapies at progression, which might impact the survival beyond the median with resultant converging curves (and disproportional hazards). RESULTS: The stratified Wilcoxon test showed a significant improvement in median (CI 95%) overall survival with DAC [7.7 (6.2; 9.2) months] versus TC [5.0 (4.3; 6.3) months; P = 0.0458]. CONCLUSION: Wilcoxon test indicated significant increase in survival for DAC versus TC compared to log-rank test. FUNDING: Janssen-Cilag GmbH. More... »

PAGES

854-862

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s12325-015-0238-9

DOI

http://dx.doi.org/10.1007/s12325-015-0238-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1053159644

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/26369324


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Azacitidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukemia, Myeloid, Acute", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Proportional Hazards Models", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Statistics as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "United States", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Janssen (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.497524.9", 
          "name": [
            "Janssen-Cilag GmbH, Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tomeczkowski", 
        "givenName": "J\u00f6rg", 
        "id": "sg:person.016250103434.63", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016250103434.63"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Hannover", 
          "id": "https://www.grid.ac/institutes/grid.9122.8", 
          "name": [
            "Center for Health Economics Research Hannover, Leibniz University Hannover, Hannover, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lange", 
        "givenName": "Ansgar", 
        "id": "sg:person.01300463471.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300463471.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.497524.9", 
          "name": [
            "Janssen-Cilag GmbH, Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "G\u00fcntert", 
        "givenName": "Andreas", 
        "id": "sg:person.01275706401.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275706401.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (Belgium)", 
          "id": "https://www.grid.ac/institutes/grid.419619.2", 
          "name": [
            "Janssen Pharmaceutica NV, Beerse, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Thilakarathne", 
        "givenName": "Pushpike", 
        "id": "sg:person.01344021601.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344021601.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (Belgium)", 
          "id": "https://www.grid.ac/institutes/grid.419619.2", 
          "name": [
            "Janssen Pharmaceutica NV, Beerse, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Diels", 
        "givenName": "Joris", 
        "id": "sg:person.0620415501.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620415501.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (United States)", 
          "id": "https://www.grid.ac/institutes/grid.497530.c", 
          "name": [
            "Janssen Research & Development, LLC, Raritan, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xiu", 
        "givenName": "Liang", 
        "id": "sg:person.0655575715.77", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655575715.77"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (Belgium)", 
          "id": "https://www.grid.ac/institutes/grid.419619.2", 
          "name": [
            "Janssen Pharmaceutica NV, Beerse, Belgium"
          ], 
          "type": "Organization"
        }, 
        "familyName": "De Porre", 
        "givenName": "Peter", 
        "id": "sg:person.01135542764.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135542764.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Janssen (Germany)", 
          "id": "https://www.grid.ac/institutes/grid.497524.9", 
          "name": [
            "Janssen-Cilag GmbH, Neuss, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tapprich", 
        "givenName": "Christoph", 
        "id": "sg:person.01002757301.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002757301.72"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2012.48.1465", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006854331"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.55.2208", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016417591"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.55.2208", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016417591"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/sim.3406", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018022135"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.44.2962", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019901430"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa0810699", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020150048"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2003-04-1205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020248554"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s13193-012-0149-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023622185", 
          "https://doi.org/10.1007/s13193-012-0149-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1038653125", 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-1-4419-1586-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038653125", 
          "https://doi.org/10.1007/978-1-4419-1586-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-1-4419-1586-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038653125", 
          "https://doi.org/10.1007/978-1-4419-1586-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.jspi.2008.05.041", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048373126"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2011.38.9429", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052466310"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1080/01621459.1999.10473847", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1058305530"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/biomet/64.1.156", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059418609"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2307/2556114", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1069991847"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2015-09", 
    "datePublishedReg": "2015-09-01", 
    "description": "INTRODUCTION: Among patients with acute myeloid leukemia (AML), the DACO-016 randomized study showed reduction in mortality for decitabine [Dacogen(\u00ae) (DAC), Eisai Inc., Woodcliff Lake, NJ, USA] compared with treatment choice (TC): at primary analysis the hazard ratio (HR) was 0.85 (95% confidence interval 0.69-1.04; stratified log-rank P = 0.108). With two interim analyses, two-sided alpha was adjusted to 0.0462. With 1-year additional follow-up the HR reached 0.82 (nominal P = 0.0373). These data resulted in approval of DAC in the European Union, though not in the United States. Though pre-specified, the log-rank test could be considered not optimal to assess the observed survival difference because of the non-proportional hazard nature of the survival curves.\nMETHODS: We applied the Wilcoxon test as a sensitivity analysis. Patients were randomized to DAC (N = 242) or TC (N = 243). One-hundred and eight (44.4%) patients in the TC arm and 91 (37.6%) patients in the DAC arm selectively crossed over to subsequent disease modifying therapies at progression, which might impact the survival beyond the median with resultant converging curves (and disproportional hazards).\nRESULTS: The stratified Wilcoxon test showed a significant improvement in median (CI 95%) overall survival with DAC [7.7 (6.2; 9.2) months] versus TC [5.0 (4.3; 6.3) months; P = 0.0458].\nCONCLUSION: Wilcoxon test indicated significant increase in survival for DAC versus TC compared to log-rank test.\nFUNDING: Janssen-Cilag GmbH.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s12325-015-0238-9", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1096634", 
        "issn": [
          "0741-238X", 
          "1865-8652"
        ], 
        "name": "Advances in Therapy", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "9", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "32"
      }
    ], 
    "name": "Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML)", 
    "pagination": "854-862", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "fd3632277114f9ad3f86d2f59f17fd5344f3b942b349808ab49a79701480a6a4"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "26369324"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8611864"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s12325-015-0238-9"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1053159644"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s12325-015-0238-9", 
      "https://app.dimensions.ai/details/publication/pub.1053159644"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T02:11", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8700_00000524.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs12325-015-0238-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s12325-015-0238-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s12325-015-0238-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s12325-015-0238-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s12325-015-0238-9'


 

This table displays all metadata directly associated to this object as RDF triples.

214 TRIPLES      21 PREDICATES      54 URIs      32 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s12325-015-0238-9 schema:about N415589fb97fc4f4cbaeebf31c88eff39
2 N57600bfac09b4db5a974c5d3fb90926d
3 N60b73682faf640f9b4a84c487f7d1511
4 N6ce9c75ac6ed47e69a59bed9c6a045ea
5 N97c2a5f630174bddbf372f769202eb94
6 N9e91a3643ddb498899807c4aac4fa149
7 Na453c58408154fb29dc16c8c6da5d3e7
8 Na7f2acf14d424bcc9124915678875437
9 Nb4994e915cbb4f018c52885db3e1e5d5
10 Nd1d243441efc4b0b8e0c2e7b7594032f
11 Ne594869dbe0d4d92b041c2cbcea5dfc5
12 anzsrc-for:11
13 anzsrc-for:1112
14 schema:author N76227c286dc5416e94f0116266158ea5
15 schema:citation sg:pub.10.1007/978-1-4419-1586-3
16 sg:pub.10.1007/s13193-012-0149-z
17 https://app.dimensions.ai/details/publication/pub.1038653125
18 https://doi.org/10.1002/sim.3406
19 https://doi.org/10.1016/j.jspi.2008.05.041
20 https://doi.org/10.1056/nejmoa0810699
21 https://doi.org/10.1080/01621459.1999.10473847
22 https://doi.org/10.1093/biomet/64.1.156
23 https://doi.org/10.1182/blood-2003-04-1205
24 https://doi.org/10.1200/jco.2011.38.9429
25 https://doi.org/10.1200/jco.2012.44.2962
26 https://doi.org/10.1200/jco.2012.48.1465
27 https://doi.org/10.1200/jco.2014.55.2208
28 https://doi.org/10.2307/2556114
29 schema:datePublished 2015-09
30 schema:datePublishedReg 2015-09-01
31 schema:description INTRODUCTION: Among patients with acute myeloid leukemia (AML), the DACO-016 randomized study showed reduction in mortality for decitabine [Dacogen(®) (DAC), Eisai Inc., Woodcliff Lake, NJ, USA] compared with treatment choice (TC): at primary analysis the hazard ratio (HR) was 0.85 (95% confidence interval 0.69-1.04; stratified log-rank P = 0.108). With two interim analyses, two-sided alpha was adjusted to 0.0462. With 1-year additional follow-up the HR reached 0.82 (nominal P = 0.0373). These data resulted in approval of DAC in the European Union, though not in the United States. Though pre-specified, the log-rank test could be considered not optimal to assess the observed survival difference because of the non-proportional hazard nature of the survival curves. METHODS: We applied the Wilcoxon test as a sensitivity analysis. Patients were randomized to DAC (N = 242) or TC (N = 243). One-hundred and eight (44.4%) patients in the TC arm and 91 (37.6%) patients in the DAC arm selectively crossed over to subsequent disease modifying therapies at progression, which might impact the survival beyond the median with resultant converging curves (and disproportional hazards). RESULTS: The stratified Wilcoxon test showed a significant improvement in median (CI 95%) overall survival with DAC [7.7 (6.2; 9.2) months] versus TC [5.0 (4.3; 6.3) months; P = 0.0458]. CONCLUSION: Wilcoxon test indicated significant increase in survival for DAC versus TC compared to log-rank test. FUNDING: Janssen-Cilag GmbH.
32 schema:genre research_article
33 schema:inLanguage en
34 schema:isAccessibleForFree true
35 schema:isPartOf Ncf87243d92724e70b9284fadd9774e5e
36 Nd04dd95d9256410d9033a0cfafbab956
37 sg:journal.1096634
38 schema:name Converging or Crossing Curves: Untie the Gordian Knot or Cut it? Appropriate Statistics for Non-Proportional Hazards in Decitabine DACO-016 Study (AML)
39 schema:pagination 854-862
40 schema:productId N8ab93c88a72d4ebd9ea0dc79144da074
41 N8fdac03a7d7c4bad90da4a485b07675b
42 Nd008216806b146c3964640019bbcf105
43 Ne0aa551f65434bdf8d12fb5873954ae5
44 Nfa6602f8c1424ea9895b67cc5a73e4e7
45 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053159644
46 https://doi.org/10.1007/s12325-015-0238-9
47 schema:sdDatePublished 2019-04-11T02:11
48 schema:sdLicense https://scigraph.springernature.com/explorer/license/
49 schema:sdPublisher Ne09595d8bdb041719d322d290abdc55a
50 schema:url http://link.springer.com/10.1007%2Fs12325-015-0238-9
51 sgo:license sg:explorer/license/
52 sgo:sdDataset articles
53 rdf:type schema:ScholarlyArticle
54 N232b7ff469734472bb13d45539d5a76a rdf:first sg:person.01344021601.48
55 rdf:rest N5cd5d6003f734a6bba248c7f51da8efb
56 N318c427d33db4f1ab46fe8b5075fa4fe rdf:first sg:person.01275706401.28
57 rdf:rest N232b7ff469734472bb13d45539d5a76a
58 N34e1abda6e104c53a6914a70a2851d69 rdf:first sg:person.0655575715.77
59 rdf:rest Na5efa6b2b08f49db91230ad89b087296
60 N415589fb97fc4f4cbaeebf31c88eff39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
61 schema:name Proportional Hazards Models
62 rdf:type schema:DefinedTerm
63 N4cd07ee943974a5297c5a8a15ea9c1a1 rdf:first sg:person.01300463471.58
64 rdf:rest N318c427d33db4f1ab46fe8b5075fa4fe
65 N57600bfac09b4db5a974c5d3fb90926d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
66 schema:name Aged
67 rdf:type schema:DefinedTerm
68 N5cd5d6003f734a6bba248c7f51da8efb rdf:first sg:person.0620415501.13
69 rdf:rest N34e1abda6e104c53a6914a70a2851d69
70 N60b73682faf640f9b4a84c487f7d1511 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Leukemia, Myeloid, Acute
72 rdf:type schema:DefinedTerm
73 N6ce9c75ac6ed47e69a59bed9c6a045ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name United States
75 rdf:type schema:DefinedTerm
76 N76227c286dc5416e94f0116266158ea5 rdf:first sg:person.016250103434.63
77 rdf:rest N4cd07ee943974a5297c5a8a15ea9c1a1
78 N8ab93c88a72d4ebd9ea0dc79144da074 schema:name readcube_id
79 schema:value fd3632277114f9ad3f86d2f59f17fd5344f3b942b349808ab49a79701480a6a4
80 rdf:type schema:PropertyValue
81 N8fdac03a7d7c4bad90da4a485b07675b schema:name dimensions_id
82 schema:value pub.1053159644
83 rdf:type schema:PropertyValue
84 N94c58ec4899342309484e799e56c4883 rdf:first sg:person.01002757301.72
85 rdf:rest rdf:nil
86 N97c2a5f630174bddbf372f769202eb94 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Antimetabolites, Antineoplastic
88 rdf:type schema:DefinedTerm
89 N9e91a3643ddb498899807c4aac4fa149 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Statistics as Topic
91 rdf:type schema:DefinedTerm
92 Na453c58408154fb29dc16c8c6da5d3e7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Male
94 rdf:type schema:DefinedTerm
95 Na5efa6b2b08f49db91230ad89b087296 rdf:first sg:person.01135542764.37
96 rdf:rest N94c58ec4899342309484e799e56c4883
97 Na7f2acf14d424bcc9124915678875437 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Humans
99 rdf:type schema:DefinedTerm
100 Nb4994e915cbb4f018c52885db3e1e5d5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Survival Rate
102 rdf:type schema:DefinedTerm
103 Ncf87243d92724e70b9284fadd9774e5e schema:volumeNumber 32
104 rdf:type schema:PublicationVolume
105 Nd008216806b146c3964640019bbcf105 schema:name nlm_unique_id
106 schema:value 8611864
107 rdf:type schema:PropertyValue
108 Nd04dd95d9256410d9033a0cfafbab956 schema:issueNumber 9
109 rdf:type schema:PublicationIssue
110 Nd1d243441efc4b0b8e0c2e7b7594032f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Female
112 rdf:type schema:DefinedTerm
113 Ne09595d8bdb041719d322d290abdc55a schema:name Springer Nature - SN SciGraph project
114 rdf:type schema:Organization
115 Ne0aa551f65434bdf8d12fb5873954ae5 schema:name pubmed_id
116 schema:value 26369324
117 rdf:type schema:PropertyValue
118 Ne594869dbe0d4d92b041c2cbcea5dfc5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Azacitidine
120 rdf:type schema:DefinedTerm
121 Nfa6602f8c1424ea9895b67cc5a73e4e7 schema:name doi
122 schema:value 10.1007/s12325-015-0238-9
123 rdf:type schema:PropertyValue
124 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
125 schema:name Medical and Health Sciences
126 rdf:type schema:DefinedTerm
127 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
128 schema:name Oncology and Carcinogenesis
129 rdf:type schema:DefinedTerm
130 sg:journal.1096634 schema:issn 0741-238X
131 1865-8652
132 schema:name Advances in Therapy
133 rdf:type schema:Periodical
134 sg:person.01002757301.72 schema:affiliation https://www.grid.ac/institutes/grid.497524.9
135 schema:familyName Tapprich
136 schema:givenName Christoph
137 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01002757301.72
138 rdf:type schema:Person
139 sg:person.01135542764.37 schema:affiliation https://www.grid.ac/institutes/grid.419619.2
140 schema:familyName De Porre
141 schema:givenName Peter
142 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135542764.37
143 rdf:type schema:Person
144 sg:person.01275706401.28 schema:affiliation https://www.grid.ac/institutes/grid.497524.9
145 schema:familyName Güntert
146 schema:givenName Andreas
147 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01275706401.28
148 rdf:type schema:Person
149 sg:person.01300463471.58 schema:affiliation https://www.grid.ac/institutes/grid.9122.8
150 schema:familyName Lange
151 schema:givenName Ansgar
152 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300463471.58
153 rdf:type schema:Person
154 sg:person.01344021601.48 schema:affiliation https://www.grid.ac/institutes/grid.419619.2
155 schema:familyName Thilakarathne
156 schema:givenName Pushpike
157 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01344021601.48
158 rdf:type schema:Person
159 sg:person.016250103434.63 schema:affiliation https://www.grid.ac/institutes/grid.497524.9
160 schema:familyName Tomeczkowski
161 schema:givenName Jörg
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016250103434.63
163 rdf:type schema:Person
164 sg:person.0620415501.13 schema:affiliation https://www.grid.ac/institutes/grid.419619.2
165 schema:familyName Diels
166 schema:givenName Joris
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0620415501.13
168 rdf:type schema:Person
169 sg:person.0655575715.77 schema:affiliation https://www.grid.ac/institutes/grid.497530.c
170 schema:familyName Xiu
171 schema:givenName Liang
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0655575715.77
173 rdf:type schema:Person
174 sg:pub.10.1007/978-1-4419-1586-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038653125
175 https://doi.org/10.1007/978-1-4419-1586-3
176 rdf:type schema:CreativeWork
177 sg:pub.10.1007/s13193-012-0149-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1023622185
178 https://doi.org/10.1007/s13193-012-0149-z
179 rdf:type schema:CreativeWork
180 https://app.dimensions.ai/details/publication/pub.1038653125 schema:CreativeWork
181 https://doi.org/10.1002/sim.3406 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018022135
182 rdf:type schema:CreativeWork
183 https://doi.org/10.1016/j.jspi.2008.05.041 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048373126
184 rdf:type schema:CreativeWork
185 https://doi.org/10.1056/nejmoa0810699 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020150048
186 rdf:type schema:CreativeWork
187 https://doi.org/10.1080/01621459.1999.10473847 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058305530
188 rdf:type schema:CreativeWork
189 https://doi.org/10.1093/biomet/64.1.156 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059418609
190 rdf:type schema:CreativeWork
191 https://doi.org/10.1182/blood-2003-04-1205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020248554
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1200/jco.2011.38.9429 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052466310
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1200/jco.2012.44.2962 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019901430
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1200/jco.2012.48.1465 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006854331
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1200/jco.2014.55.2208 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016417591
200 rdf:type schema:CreativeWork
201 https://doi.org/10.2307/2556114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1069991847
202 rdf:type schema:CreativeWork
203 https://www.grid.ac/institutes/grid.419619.2 schema:alternateName Janssen (Belgium)
204 schema:name Janssen Pharmaceutica NV, Beerse, Belgium
205 rdf:type schema:Organization
206 https://www.grid.ac/institutes/grid.497524.9 schema:alternateName Janssen (Germany)
207 schema:name Janssen-Cilag GmbH, Neuss, Germany
208 rdf:type schema:Organization
209 https://www.grid.ac/institutes/grid.497530.c schema:alternateName Janssen (United States)
210 schema:name Janssen Research & Development, LLC, Raritan, NJ, USA
211 rdf:type schema:Organization
212 https://www.grid.ac/institutes/grid.9122.8 schema:alternateName University of Hannover
213 schema:name Center for Health Economics Research Hannover, Leibniz University Hannover, Hannover, Germany
214 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...